The first half of 2026 was the most disruptive period in SBIR history. A six-month lapse, a $30M new award mechanism, record-low NIH success rates, $1.27B in CDMRP funding, and a tightening VC market. Here’s the full data picture — and what it means for your funding strategy.
After a six-month freeze, SBIR and STTR programs are officially reauthorized through 2031. Here’s what changed — the new $30M Strategic Breakthrough Award, the 9-proposal cap, Direct-to-Phase II STTR — and what you need to do right now.
Website Links
Address
FreeMind Group
6 Liberty Square #2783
Boston, MA 02109